Cordycepin-enriched Cordyceps militaris induces immunomodulation and tumor growth delay in mouse-derived breast cancer

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1996-2002

  Jeong, Min Ho ^a,b   Lee, Chang Min ^a   Lee, Sang Wha ^a,b   Seo, Su Yeong ^a,b   Seo, Min Jeong ^b   Kang, Byoung Won ^b   Jeong, Yong Kee ^b   Choi, Yoo Jin ^c   Yang, Kwang Mo ^c   Jo, Wol Soon ^c  

^a Dong A University College of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Antitumor immunity; Cordycepin; Cordyceps militaris; Cytotoxic T lymphocyte; FM3A cell; Treg cell

Indexed keywords

CONCANAVALIN A; CORDYCEPIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORDYCEPS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FUNGAL STRAIN; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CORDYCEPS; DEOXYADENOSINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; MICE; MICE, INBRED C3H; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84882730172     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2660     Document Type: Article

References (35)

1. Cunningham KG, Manson W, Spring FS and Hutchinson SA: Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.). Nature 166: 949, 1950.
2. Paterson RR: Cordyceps: a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry 69: 1469-1495, 2008.
3. Kim HG, Shrestha B, Lim SY, et al: Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur J Pharmacol 545: 192-199, 2006.
4. Yun Y, Han S, Lee S, Ko S, Lee C, Ha N and Kim K: Anti-diabetic effects of CCCA, CMESS, and cordycepin from Cordyceps militaris and the immune responses in streptozotocin-induced diabetic mice. Nat Prod Sci 9: 291-298, 2003.
5. Ahn YJ, Park SJ, Lee SG, Shin SC and Choi DH: Cordycepin: selective growth inhibitor derived from liquid culture of Cordyceps militaris against Clostridium spp. J Agric Food Chem 48: 2744-2748, 2000.
6. Sugar AM and McCaffrey RP: Antifungal activity of 3'-deoxyadenosine (cordycepin). Antimicrob Agents Chemother 42: 1424-1427, 1998.
7. Müller WE, Weiler BE, Charubala R, et al: Cordycepin analogues of 2',5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. Biochemistry 30: 2027-2033, 1991.
8. Kodama EN, McCaffrey RP, Yusa K and Mitsuya H: Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem Pharmacol 59: 273-281, 2000.
9. Cho MA, Lee DS, Kim MJ, Sung JM and Ham SS: Antimutagenicity and cytotoxicity of cordycepin isolated from Cordyceps militaris. Food Sci Biotechnol 12: 472-475, 2003.
10. Nakamura K, Konoha K, Yoshikawa N, Yamaguch Y, Kagota S, Shinozuka K and Kunitomo M: Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice. In Vivo 19: 137-141, 2005.
11. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Antitumor effect of cordycepin (3'-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res 26: 43-48, 2006.
12. Thomadaki H, Scorilas A, Tsiapalis CM and Havredaki M: The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol 61: 251-265, 2008.
13. Jeong JW, Jin CY, Park C, et al: Induction of apoptosis by cordycepin via reactive oxygen species generation in human leukemia cells. Toxicol In Vitro 25: 817-824, 2011.
14. Odunsi K and Old LJ: Tumor infiltrating lymphocytes: indicators of tumor-related immune responses. Cancer Immun 7: 3, 2007.
15. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274, 2005.
16. Jeong MH, Seo MJ, Park JU, et al: Effect of cordycepin purified from Cordyceps militaris on Th1 and Th2 cytokines in mouse splenocytes. J Microbiol Biotechnol 22: 1161-1164, 2012.
17. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
18. Curiel TJ: Regulatory T cells and treatment of cancer. Curr Opin Immunol 20: 241-246, 2008.
19. Liu Z, Kim JH, Falo LDJ and You Z: Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol 182: 6160-6167, 2009.
20. Malmberg KJ: Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53: 879-892, 2004.
21. Horowitz B, Goldfinger BA and Marmur J: Effect of cordycepin triphosphate on the nuclear DNA-dependent RNA polymerases and poly(A) polymerase from the yeast, Saccharomyces cerevisiae. Arch Biochem Biophys 172: 143-148, 1976.
22. Muller WE, Seibert G, Beyer R, Breter HJ, Maidhof A and Zahn RK: Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res 37: 3824-3833, 1977.
23. Rosenberg SA: Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180-199, 1992.
24. von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol 6: 338-344, 2005.
25. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F and Sakaguchi S: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162: 5317-5326, 1999.
26. Takahashi T, Kuniyasu Y, Toda M, et al: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980, 1998.
27. de la Rosa M, Rutz S, Dorninger H and Scheffold A: Interleukin-2 is essential for CD25+CD4+ regulatory T cell function. Eur J Immunol 34: 2480-2488, 2004.
28. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N and Lafaille JJ: Interleukin 2 signaling is required for CD4+ regulatory T cell function. J Exp Med 196: 851-857, 2002.
29. Yao Z, Kanno Y, Kerenyi M, et al: Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109: 4368-4375, 2007.
30. Yamagiwa S, Gray JD, Hashimoto S and Horwitz DA: A role for TGF-β in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 166: 7282-7289, 2001.
31. Ghiringhelli F, Puig PE, Roux S, et al: Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202: 919-929, 2005.
32. Chen W, Jin W, Hardegen N, et al: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198: 1875-1886, 2003.
33. Valérie D, Amit A, Hyoung K, et al: IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3-effector T cells. Nat Immunol 9: 1347-1355, 2008.
34. Xiaoyu H and Lionel BL: Cross-regulation of signaling pathway by interferon-γ: implication for immune response and autoimmune diseases. Immunity 31: 539-550, 2009.
35. Chen ML, Pittet MJ, Gorelik L, et al: Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci 102: 419-424, 2005.